SNEDDS curcumin formulation leads to enhanced protection from pain and functional deficits associated with diabetic neuropathy: an insight into its mechanism for neuroprotection.
Curcumin has shown to be effective against various diabetes related complications. However major limitation with curcumin is its low bioavailability. In this study we formulated and characterized self nano emulsifying drug delivery system (SNEDDS) curcumin formulation to enhance its bioavailability and then evaluated its efficacy in experimental diabetic neuropathy. Bioavailability studies were performed in male Sprague Dawley rats. Further to evaluate the efficacy of formulation in diabetic neuropathy various parameters like nerve function and sensorimotor perception were assessed along with study of inflammatory proteins (NF-κB, IKK-β, COX-2, iNOS, TNF-α and IL-6). Nanotechnology based formulation resulted in prolonged plasma exposure and bioavailability. SNEDDS curcumin provided better results against functional, behavioural and biochemical deficits in experimental diabetic neuropathy, when compared with naive curcumin. Further western blot analysis confirmed the greater neuroprotective action of SNEDDS curcumin. SNEDDS curcumin formulation due to higher bioavailability was found to afford enhanced protection in diabetic neuropathy.


BACKGROUND
In this study the authors formulated and characterized a self-emulsifying drug delivery system for formulation to enhance curcumin bioavailability in experimental diabetic neuropathy. Enhanced efficacy was demonstrated in a rat model.
Molecular Neuropharmacology Laboratory, Department of Pharmacology and Toxicology, National Institute of Pharmaceutical Education and Research (NIPER), Punjab, India.
Rayanta P
RP
Joshi
Geeta
G
Negi
Ashutosh
A
Kumar
Yogesh B
YB
Pawar
Bhushan
B
Munjal
Arvind K
AK
Bansal
Shyam S
SS
Sharma
D000818:Animals; D001682:Biological Availability; D003474:Curcumin / Q000008:administration & dosage* / Q000737:chemistry; D003929:Diabetic Neuropathies / Q000150:complications / Q000188:drug therapy* / Q000473:pathology; D016503:Drug Delivery Systems; D004655:Emulsions / Q000008:administration & dosage / Q000737:chemistry; D006801:Humans; D008297:Male; D053758:Nanoparticles / Q000008:administration & dosage* / Q000737:chemistry; D018696:Neuroprotective Agents; D010146:Pain / Q000150:complications / Q000188:drug therapy* / Q000473:pathology; D051381:Rats
D004655:Emulsions; D018696:Neuroprotective Agents; D003474:Curcumin
Curcumin; Diabetic neuropathy; NF-κB; SNEDDS formulation